[go: up one dir, main page]

MA31265B1 - Treatment of human cancer by IL-18 antibodies coupled with anti-CD20. - Google Patents

Treatment of human cancer by IL-18 antibodies coupled with anti-CD20.

Info

Publication number
MA31265B1
MA31265B1 MA32235A MA32235A MA31265B1 MA 31265 B1 MA31265 B1 MA 31265B1 MA 32235 A MA32235 A MA 32235A MA 32235 A MA32235 A MA 32235A MA 31265 B1 MA31265 B1 MA 31265B1
Authority
MA
Morocco
Prior art keywords
treatment
human cancer
antibodies coupled
human
antibodies
Prior art date
Application number
MA32235A
Other languages
Arabic (ar)
French (fr)
Inventor
Zdenka Haskova
Zdenka Ludmila Jonak
Stephen H Trulli
John F Toso
Margaret N Whitacre
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39788932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31265(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA31265B1 publication Critical patent/MA31265B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne d'une manière générale l'utilisation de l'il-18 humaine en combinaison dans le traitement de cancers. Cette invention concerne en particulier l'utilisation de l'il-18 humaine combinée à un anticorps anti-cd20.The present invention relates generally to the use of human IL-18 in combination in the treatment of cancers. This invention particularly relates to the use of human il-18 combined with an anti-cd20 antibody.

MA32235A 2007-03-23 2009-09-24 Treatment of human cancer by IL-18 antibodies coupled with anti-CD20. MA31265B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89685507P 2007-03-23 2007-03-23
US95200207P 2007-07-26 2007-07-26
PCT/US2008/057620 WO2008118736A1 (en) 2007-03-23 2008-03-20 Combined human il- 18 and anti cd20 antibody cancer treatment

Publications (1)

Publication Number Publication Date
MA31265B1 true MA31265B1 (en) 2010-03-01

Family

ID=39788932

Family Applications (2)

Application Number Title Priority Date Filing Date
MA32235A MA31265B1 (en) 2007-03-23 2009-09-24 Treatment of human cancer by IL-18 antibodies coupled with anti-CD20.
MA32234A MA31264B1 (en) 2007-03-23 2009-09-24 Methods of treating cancer comprising administering human il-18 in combination

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA32234A MA31264B1 (en) 2007-03-23 2009-09-24 Methods of treating cancer comprising administering human il-18 in combination

Country Status (21)

Country Link
US (4) US20090035258A1 (en)
EP (3) EP2129398A4 (en)
JP (2) JP2010522200A (en)
KR (2) KR20100015798A (en)
CN (1) CN101678102A (en)
AR (2) AR065803A1 (en)
AU (2) AU2008231025A1 (en)
BR (2) BRPI0809079A2 (en)
CA (2) CA2681827A1 (en)
CL (2) CL2008000818A1 (en)
CR (2) CR10996A (en)
DO (2) DOP2009000208A (en)
EA (2) EA200970885A1 (en)
IL (2) IL200525A0 (en)
MA (2) MA31265B1 (en)
MX (2) MX2009010269A (en)
NZ (1) NZ579179A (en)
PE (2) PE20090190A1 (en)
SG (1) SG171674A1 (en)
TW (2) TW200906436A (en)
WO (2) WO2008118736A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102206277A (en) * 2000-02-10 2011-10-05 雅培制药有限公司 Antibodies that bind human interleukin-18 and methods of making and using
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
PE20090190A1 (en) * 2007-03-23 2009-03-22 Smithkline Beecham Corp COMBINATION OF ANTI-CD20 ANTIBODIES AND IL-18 POLYPEPTIDES
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding protein
LT3134124T (en) 2014-04-25 2019-05-27 Pierre Fabre Médicament Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
PT3134125T (en) 2014-04-25 2020-01-13 Pf Medicament Antibody-drug-conjugate and its use for the treatment of cancer
CA2957387A1 (en) * 2014-08-07 2016-02-11 Hyogo College Of Medicine Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody
WO2016126615A1 (en) * 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US20240368247A1 (en) * 2020-12-02 2024-11-07 The Royal Institution For The Advancement Of Learning/Mcgill University Therapeutic applications of type 1 insulin-like growth factor (igf-1) receptor antagonists
WO2025033330A1 (en) * 2023-08-04 2025-02-13 医療革新国際連携株式会社 Antitumor therapy by combined use of chymase inhibitor and immunotherapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69519454T2 (en) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein that induces interferon gamma production and monoclonal antibodies against it
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
JP4004088B2 (en) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 Protein that induces production of interferon-γ in immunocompetent cells
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
US5680795A (en) 1995-07-05 1997-10-28 Norco Inc. Mechanical drive assembly incorporating counter-spring biassed radially-adjustable rollers
JP4024366B2 (en) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 Polypeptide
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
PL208592B1 (en) * 2000-06-15 2011-05-31 Smithkline Beecham Corp Method for obtaining active polypeptide precursor polypeptide, method for obtaining active human IL-18 polypeptide from precursor polypeptide and method for obtaining active human IL-18 polypeptide from human precursor polypeptide
US20020094323A1 (en) * 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
CN101914158A (en) * 2002-02-14 2010-12-15 免疫医疗公司 Anti-cd20 antibodies and fusion proteins thereof and methods of use
US20040001828A1 (en) * 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
ATE497778T1 (en) * 2002-09-16 2011-02-15 Agennix Inc LACTOFERRIN COMPOSITIONS AND METHODS FOR TREATING DIABETIC ULCUS
WO2004032962A1 (en) * 2002-10-08 2004-04-22 Immunomedics, Inc. Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents
SI1558648T1 (en) * 2002-10-17 2012-05-31 Genmab As Human monoclonal antibodies against cd20
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
WO2004091517A2 (en) * 2003-04-15 2004-10-28 Smithkline Beecham Corporation Conjugates comprising human il-18 and substitution mutants thereof
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
US7109304B2 (en) * 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
RU2412199C2 (en) * 2005-04-18 2011-02-20 Ново Нордиск А/С Versions of il-21
KR20080030673A (en) * 2005-07-21 2008-04-04 젠맵 에이/에스 Efficacy Assay for Antibody Drug Ingredients That Bind Fc Receptors
WO2008008981A1 (en) * 2006-07-13 2008-01-17 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
CA2662609A1 (en) * 2006-09-14 2008-03-20 The Trustees Of The University Of Pennsylvania Modulation of regulatory t cells by human il-18
PE20090190A1 (en) * 2007-03-23 2009-03-22 Smithkline Beecham Corp COMBINATION OF ANTI-CD20 ANTIBODIES AND IL-18 POLYPEPTIDES

Also Published As

Publication number Publication date
AR065803A1 (en) 2009-07-01
KR20100015798A (en) 2010-02-12
SG171674A1 (en) 2011-06-29
AU2008231114A1 (en) 2008-10-02
CL2008000818A1 (en) 2008-09-26
EP2129398A4 (en) 2010-04-21
CR11075A (en) 2010-03-22
IL200863A0 (en) 2010-05-17
AR065818A1 (en) 2009-07-01
DOP2009000208A (en) 2010-03-31
EP2136841A4 (en) 2010-07-07
KR20100014530A (en) 2010-02-10
AU2008231025A1 (en) 2008-10-02
TW200904469A (en) 2009-02-01
NZ579179A (en) 2011-12-22
MX2009010271A (en) 2009-10-12
CR10996A (en) 2009-11-12
WO2008118733A3 (en) 2008-11-27
CA2681827A1 (en) 2008-10-02
US20100196310A1 (en) 2010-08-05
BRPI0809079A2 (en) 2019-03-06
CL2008000842A1 (en) 2008-10-17
PE20090184A1 (en) 2009-03-22
BRPI0808943A2 (en) 2014-08-26
WO2008118733A2 (en) 2008-10-02
MA31264B1 (en) 2010-03-01
EP2129398A1 (en) 2009-12-09
JP2010522239A (en) 2010-07-01
WO2008118736A1 (en) 2008-10-02
DOP2009000220A (en) 2009-10-31
EP2338514A1 (en) 2011-06-29
IL200525A0 (en) 2010-04-29
JP2010522200A (en) 2010-07-01
EA200970885A1 (en) 2010-02-26
EA200970884A1 (en) 2010-04-30
CN101678102A (en) 2010-03-24
US20090035258A1 (en) 2009-02-05
TW200906436A (en) 2009-02-16
PE20090190A1 (en) 2009-03-22
EP2136841A2 (en) 2009-12-30
CA2681851A1 (en) 2008-10-02
US20080274078A1 (en) 2008-11-06
MX2009010269A (en) 2009-10-12
US20100111945A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
MA31265B1 (en) Treatment of human cancer by IL-18 antibodies coupled with anti-CD20.
MA33470B1 (en) Composite treatment consisting mainly of antibodies against cd20 and fludrapin
UA106194C2 (en) Diagnosis and treatment of cancer using anti-ereg antibody
MA34059B1 (en) ANTI-ANGIOGENIC THERAPY FOR THE TREATMENT OF OVARIAN CANCER
GT200500298A (en) FORMULATIONS OF ANTIBODIES
MA33276B1 (en) Cadherine-17 antibodies
MA52742B1 (en) DLL3-CD3 BISPECIFIC ANTIBODIES
UA105760C2 (en) ANTIBODY AGAINST BST2
EA200802182A1 (en) MODIFIED HUMANIZED ANTIBODIES AGAINST INTERLEUKIN-18
MA33757B1 (en) Il-23 human antigen binding protein
UA109633C2 (en) HUMAN ANTIBODY AGAINST TISSUE FACTOR
MA37946A1 (en) Treatment of rheumatoid arthritis
MA34277B1 (en) PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
GT200900167A (en) HUMAN ANTIBODIES AGAINST LEAGUE 4 OF HUMAN DELTA TYPE.
CY1118549T1 (en) USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMISTRY FOR TREATMENT OF BREAST CANCER
MA31984B1 (en) Formulation of antibodies
CO6710903A2 (en) An antibody that specifically recognizes and binds with a phospho-epitope in the mammalian tau protein or in one of its fragments and a composition comprising the same
CR10730A (en) ANTI NOTCH3 AGONIST ANTIBODIES AND THEIR USE IN THE TREATMENT OF DISEASES RELATED TO THE NOTCH3 GENE
MX2018011832A (en) METHODS AND COMPOSITIONS FOR USE IN THE DIAGNOSIS OF PATIENTS WITH CANCER.
MA33323B1 (en) ADJUVANT THERAPY OF CANCER
EP2597464A3 (en) Metabolomic profiling of prostate cancer
MA53069B1 (en) Igf-1r antibody and its use as a targeting vehicle for the treatment of cancer
EA201100779A1 (en) COMPOSITIONS OF ANTIBODIES TO CXCR1 AND METHODS OF THEIR APPLICATION
MA38273A1 (en) Combination therapy with anti-her3 antibodies
FR2942798B1 (en) PEPTIDES USEFUL FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA